# Genomic Locus Modulating IOP in the BXD RI Mouse Strains

Rebecca King[1], Ying Li[1], Jiaxing Wang[1,2], Felix L. Struebing[1] and Eldon E. Geisert[1]

[1]Department of Ophthalmology, Emory University 1365B Clifton Road NE Atlanta GA, 30322

[2]Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China

Corresponding Author:        Eldon E. Geisert
Professor of Ophthalmology
Emory University
1365B Clifton Road NE
Atlanta GA 30322
email: egeiser@emory.edu
Phone: 404-778-4239

**Abstract**

Purpose: Intraocular pressure (IOP) is the primary risk factor for developing glaucoma. The present study examines genomic contribution to the normal regulation of IOP in the mouse.

Methods: The BXD recombinant inbred (RI) strain set was used to identify genomic loci modulating IOP. We measured the IOP from 532 eyes from 33 different strains. The IOP data will be subjected to conventional quantitative trait analysis using simple and composite interval mapping along with epistatic interactions to define genomic loci modulating normal IOP.

Results: The analysis defined one significant quantitative trait locus (QTL) on Chr.8 (100 to 106 Mb). The significant locus was further examined to define candidate genes that modulate normal IOP. There are only two good candidate genes within the 6 Mb over the peak, *Cdh8* (Cadherin 8) and *Cdh11* (Cadherin 11). Expression analysis on gene expression and immunohistochemistry indicate that *Cdh11* is the best candidate for modulating the normal levels of IOP.

Conclusions: We have examined the genomic regulation of IOP in the BXD RI strain set and found one significant QTL on Chr. 8. Within this QTL that are two potential candidates for modulating IOP with the most likely gene being *Cdh11*.

## Introduction

Glaucoma is a diverse set of diseases with heterogeneous phenotypic presentations associated with different risk factors. Untreated, glaucoma leads to permanent damage of axons in the optic nerve and visual field loss. Millions of people worldwide are affected [1, 2] and it is the second leading cause of blindness in the United States [3]. Adult-onset glaucoma is a complex collection of diseases with multiple risk factors and genes with differing magnitudes of effects on the eventual loss of RGCs. The severity of the disease appears to be dependent on the interaction of multiple genes, age, and environmental factors [4]. There are also a number of phenotypic risk factors for POAG including: age, ethnicity, central corneal thickness and axial length[5]. The primary risk factor is an elevated intraocular pressure (IOP) [6]. There are known genetic mutations that affect IOP that result in inherited glaucoma [7, 8]. The prime example is MYOC, a protein secreted by the trabecular meshwork and mutations in this protein cause ER stress which results in a decrease in the function of the trabecular meshwork and an elevation in IOP [9, 10]. We know a considerable amount about the regulation of IOP from the production of aqueous humor to the outflow pathways. IOP is a complex trait affected by different tissues in the eye each of which is regulated by multiple genomic loci. Interestingly, there are very few studies that have identified genomic loci modulating normal IOP.

In the present study, we are using the BXD RI strain set that is particularly suited for the study of genetics and the effects on the severity of glaucoma. This genetic reference panel presently consists of 80 strains [11], and we are now in the unique position of being able to study the eyes of more than 80 strains with shuffled genomes from the two parental strains, C57BL/6J and the DBA/2J. There are over 7,000 break points in our current set of BXD strains. For this study, our group has measured IOP of 532 eyes from 33 strains to identify genomic loci modulating IOP. A systems genetics approach to glaucoma is a relatively new branch of quantitative genetics that has the goal of understanding networks of interactions across multiple levels that link DNA variation to phenotype [12]. Systems genetics involves an analysis of sets of causal interactions among classic traits such as IOP, networks of gene variants, and developmental, environmental, and epigenetic factors. The main challenge is the need for comparatively

large sample size and the use of more advanced statistical and computational methods

and models. We finally have a sufficiently large number of strains to use this approach

[13, 14]. Our goal is now to combine data across several levels from DNA to ocular

phenotype and analyze them with newly developed computational methods to understand

pre-disease susceptibility to glaucoma along with the genetic networks modulating the

response of the eye to elevated IOP.

**Methods**

Mice: This study measured the IOP in the 33 BXD strains of mice along with the parental

strains the C57BL/6J mouse strain and the DBA/2J mouse strain. None of the BXD

strains included in this study carried both mutations (*Tyrp1* and *Gpnmb*) known to cause

the severe glaucoma phenotype observed in the DBA2/J strain. All of the mice in this

study were between 60 and 120 days of age, a time before there is any significant

elevation in IOP due pigment dispersion [15]. The data presented in this paper is based on

measurements from 532 eyes with roughly equal numbers of male and female mice. All

breeding stock was ordered from Jackson Laboratories (Bar Harbor, ME) and maintained

at Emory. Mice were housed in the animal facility at Emory University, maintained on a

12 hr light/dark cycle (lights on at 0700), and provided with food and water ad libitum.

IOP measurement were made between 0900 and 1100. Both eyes were measured and the

data from each eye was entered into the database. An induction–impact tonometer

(Tonolab Colonial Medical Supply) was used to measure the IOP according to

manufacturer's instructions and as previously described (Saleh M, Nagaraju M, Porciatti

2007; Nagaraju M, Saleh M, Porciatti V 2009). Mice were anesthetized with Avertin (334

mg/kg) or ketamine/xylazine (100,15mg/kg). Three consecutive IOP readings for each

eye were averaged. IOP readings obtained with Tonolab have been shown to be accurate

and reproducible in various mouse strains, including DBA/2J (Wang et al., 2005). All

measurements were taken approximately 10 minutes after the induction of anesthesia.

These IOP measurements were made on mice prior to two different experimental

procedures, blast injury to the eye or elevation of IOP by injection of magnetic beads into

the anterior chamber. When we compared the IOP of animals anesthetized with Avertin

to those anesthetized with ketamine/xylazine over the entire dataset there was not

significant difference between the two groups. We did a similar comparison looking only

at the C57BL/6J mice with 11 mice anesthetized with Avertin (mean IOP 10.2, SD 0.15)

and 27 mice anesthetized with ketamine/xylazine (mean IOP 11.2, SD 2.9) and there was

no statistically significant difference between the two groups using a student *t*-test.

**Interval Mapping of IOP Phenotype:** The IOP data will be subjected to conventional

QTL analysis using simple and composite interval mapping along with epistatic

interactions. Genotype was regressed against each trait using the Haley-Knott equations

implemented in the WebQTL module of GeneNetwork [16] [17] [18]. Empirical

significance thresholds of linkage are determined by permutations [19]. We correlate

phenotypes with expression data for whole eye and retina generated [13, 20, 21].

**Immunohistochemistry:** For immunohistochemical experiments mice were deeply

anesthetized with a mixture of 15 mg/kg of xylazine (AnaSed) and 100 mg/kg of

ketamine (Ketaset) and perfused through the heart with saline followed by 4%

paraformaldehyde in phosphate buffer (pH 7.3). The eye were embedded in paraffin as

described by Sun et al., [22]. The eyes were dehydrated in a series of ethanol and xylenes

changes for 20 minutes each (50% ETOH, 70% ETOH, 90% ETOH, 95% ETOH, two

changes of 100% ETOH, 50% ETOH with 50% xylenes, two changes of 100% xylenes,

two changes of paraffin. The eyes were then embedded in paraffin blocks. The eyes were

sectioned with a rotary microtome at 10µm and mounted on glass slides. The sections

were deparaffinized and rehydrated. The sections were rinsed in PBS, and then placed in

blocking buffer containing 2% donkey serum, 0.05% DMSO and 0.05% Triton X-100 for

30 min. The sections were rinsed in PBS, and then placed in blocking buffer containing 2%

donkey serum, 0.05% DMSO and 0.05% Triton X-100 for 30 min. The sections were

incubated in primary antibodies (1:500) against Cadherin 11 (Thermofisher, Cat. #71-

7600, Waltham, MA) overnight at 4°C. After rinsing, the sections were incubated with

secondary antibody conjugated to AlexaFluor-488 (donkey anti-rabbit, Jackson

Immunoresearch Cat #711-545-152, Westgrove, PA) , (1:1000), for 2 hours at room

temperature. The sections were then rinsed 3 times in PBS for 15 minutes each. Then

they were counterstained with TO-PRO-3 iodide was purchased from Invitrogen (T3605,

Invitrogen, Eugene OR). The slides were flooded with Fluoromount-G (SouthernBiotech

Cat #. 0100-01, Birmingham, AL), and covered with a coverslip. All images were

photographed using on Nikon Eclipse TE2000-E (Melville, NY) confocal and images

were acquired by Nikon's EZ-C1 Software (Bronze Version, 3.91).

**PCR Validation**:  Reverse transcription-quantitative polymerase chain reaction (RT-

qPCR) were used to validate the mRNA expression level of Cdh11 and Cdh8 and Myoc

in whole eyes of C57BL/6J mice. Primers were designed for Cdh11, Cdh8 and Myoc

using Primer BLAST-NCBI so that predicted PCR products were approximately 150bp.

The cycle threshold values were normalized to a mouse housekeeping gene

peptidylprolyl isomerase A (Ppia). Sequences of the PCR primers are listed in

supplementary Table I. PCR reactions were carried out in 10μl reactions containing 5μl

of 2x QuantiTect SYBR Green PCR Master Mix (Qiagen, Cat #204141 Hilden,

Germany), 0.5 μl of forward primer (0.5μM), 0.5 μl of reverse primer (0.5 μM), 2μl of

template cDNA(10ng) and 2μl of RNA free $H_2O$. PCR of mouse genes was performed

using a program beginning at 95°C for 15 min, followed by 40 cycles of reaction with

denaturation at 94°C for 15 sec, annealing at 59°C for 30 sec and extension at 72°C for

30 sec of each cycle.

**Results**

The overall goal of the present investigation was to determine if specific genomic loci

modulate IOP in the BXD RI strains. IOP was measured in 532 eyes form 33 BXD RI

strains and the two parental strains C57BL/6J mouse and DBA2/J mouse. To create a

mapping file the strain averages and standard errors were calculated (Figure 1). The IOP

measured across the 33 strains was 13.2 mmHg and the standard deviation was 1.5

mmHg. The strain with the lowest IOP was DBA2/J, with an average IOP of 10.9 mmHg.

The strain with the highest IOP was BXD48 with an average IOP of 17.1 mmHg. The

IOP of the parental strains was 11.6 mmHg for the C57BL/6J and 10.9 mmHg for the

DBA2/J. This is a substantial amount of genetic transgression across the BXD RI strain

set. This type of phenotypic variability is a clear indication that IOP is in fact a complex

trait. These data can also be used to calculate the heritability of IOP. Figure 1 reveals a

considerable variability in the IOP from strain to strain and the standard error for each

strain is rather small. This type of data suggests that the genetic variability has a greater

effect than the environmental variability. These data can be used to calculate the

heritability of IOP. To calculate heritability ($H^2$) is the genetic variance (Vg) of the trait is

divided by the sum of genetic variance plus the environmental variance (Vg +Ve). The

genetic variance can be estimated by taking the standard deviation of the mean of IOP for

each strain (Vg = 1.5 mmHg). The environmental variance can be estimated by taking the

mean of the standard deviation across the strain (Ve = 3.3 mmHg).  Using the formula for

heritability, $H^2$ = Vg/(Vg + Ve), the calculation of 1.5 mmHg /(1.5 mmHg + 3.3 mmHg)

reveals that $H^2$ = 0.31.6. Thus, IOP is a heritability trait in the BXD RI strain set.

**Genome Wide Mapping:**  Taking the average IOP from 33 strains of mice we performed

an unbiased genome wide scan to identify genomic loci (QTLs) that modulate IOP. The

genome-wide interval map (Figure 2) identifies on significant peak on Chr. 8. Examining

an expanded view of Chr.8, 90 to 120 Mb (Figure 3), the peak of the IOP QTL reaches

significance form 100 Mb to 106 Mb. BXD strains with higher IOPs (Figure 3B) tend to

have the C57BL/6J allele (red) and strains with lower IOPs tend to have the DBA2/J

allele (green). When the distribution of genes within this region is examined (gene track

Figure 3A) the significant portion of the QTL peak covers a region of the genome that is

a gene desert. Within this region there are only 5 genes: *Arl5a* (ADP-ribosylation factor-

like 5a), *Cdh11* (cadherin11), *Cdh8* (cadherin 8), *Gm15679* (predicted gene 15679) and

*Rplp0* (ribosomal protein, large, P0). Using the tools available on GeneNetwork

(genenetwork.org) we are able to identify potential candidates for modulating IOP in the

BXD RI strains. The candidate genes can either be genomic elements with cis-QTLs or

they can be genes with nonsynonymous SNPs changing protein sequence. Within this

region there are only two putative candidate genes.  There are cisQTL for *Cdh11*(exon

probes 17512155 and 17512156, build 2016-12-12 GeneNetwork). There are two genes

in this region with non-synonymous SNPs, *Cdh11* and *Cdh8*. Thus, there is a single QTL

modulating IOP and this peak lies in a gene desert with only two good candidate genes
*Cdh11* and *Cdh8*.

For the initial evaluation of the two candidate genes we examined their expression level
in microarray datasets hosted on GeneNetwork: the eye database (Eye M430v2 (Sep08)
RMA) and retina database (DoD Retina Normal Affy MoGene 2.0 ST (May15) RMA
Gene Level). In the eye dataset, the highest level of expression for a Cdh11 probe set
(1450757_at) is 10.8 $Log_2$, while for *Cdh8* (1422052_at) the highest level of expression
is 7.3 $Log_2$. For this dataset the mean expression of mRNA in the retina is set to 8. Thus,
*Cdh11* is expressed at levels higher than the mean and *Cdh8* is expressed at levels below
the average expression level. Furthermore, in the whole eye database, there is over an 8-
fold increase in expression of *Cdh11* relative to *Cdh8*. In the retina database, *Cdh11*
(probe set 17512153) had an expression level of 10.9 and *Cdh8* (probe set 17512121) had
an expression level of 9.3, indicating that within the retina proper *Cdh11* is expression is
2-fold higher than *Cdh8*.

To confirm the expression levels of *Cdh11* and *Cdh8* in the eye, we examined the levels
of mRNA in the whole eye by RT-qPCR. In 4 biological replicate RNA samples, we
examined the levels of *Cdh11, Cdh8* and *Myoc* (a marker of trabecular meshwork cells,
[23]). Our PCR analysis confirmed the general findings of the microarray data sets. In
the 4 biological samples of whole eye, *Cdh11* was more highly expressed than *Cdh8*. The
average of the 4 samples demonstrated a more than 2-fold higher expression of *Cdh11*
than *Cdh8*. *Myoc* was also expressed at a higher level than *Cdh8* but at approximately at
the same level as *Cdh11*. All of these data taken together indicate that *Cdh11* is the prime
candidate for an upstream modulator of IOP.

**Distribution of Cadherin 11 in the Eye:** To determine if cadherin 11 is found in
structures associated with the control of IOP, we stained sections of the eye for cadherin
11. In these sections, there was a considerable amount of antibody-specific staining (Fig.
4A). This label is not observed in control sections stained with secondary antibody only
(Fig. 4B). There is extensive labeling of all layers of the cornea. The epithelium of the

ciliary body is also heavily labeled as well as labeling of pars plana. There is also light
labeling of the retina.  At higher magnification (Fig. 4C), clear labeling of the trabecular
meshwork (arrow). Thus, cadherin 11 is expressed in the cells of the trabecular
meshwork, the primary structure involved in regulating IOP.

**Discussion**
The normal regulation of intraocular pressure is a balance between production in the
ciliary body and outflow [24, 25]. In the human, IOP ranges can range from a relatively
low pressures to extremely high that occur in acute angle closure glaucoma. It is
generally accepted that the "normal" range for IOP in humans is from 12mmHg to
22mmHg [26, 27]. In addition, monitoring throughout the day reveals IOP is pulsatory
and has a diurnal variability [28]. These findings tell an interesting story about the
regulation of pressure in the eye; however, the primary driving force behind the intense
investigation of IOP in humans is that fact that it is the primary risk factor for developing
glaucoma [29]. Furthermore, all of the current treatments for glaucoma center around
lowering IOP either by pharmacological approaches or surgery [30, 31].

The association of elevated IOP and glaucoma, has driven most of the study of IOP in
human populations [5, 32, 33].  Most of these studies involve the study of glaucoma, but
a few have a primary focused on the regulation of IOP.  These studies have found that
IOP is a heritable trait with estimates of heritability ranging from 0.39 to 0.64 [6, 34-36].
In the present study, we found that the heritability of IOP in the BXD RI strains was 0.36.
Thus, the mouse strains demonstrated a heritability near the lower end of the human
populations.  The interest has prompted studies to identify genes regulating IOP. In a
genome-wide association study of IOP involving 11,972 subjects, significant associations
were observed with SNPs in two genes, *GAS7* and *TMCO1* [37]. Both of these genes are
expressed at high levels in the ciliary body and trabecular meshwork [38] and both of the
genes interact with known glaucoma risk genes [37]. TMCO1 is also known to be
associated with sever glaucoma risk [39].

In an effort to understand the regulation of IOP and its effects on the retina, many
research groups have used inbred mouse strains [40-44]. IOP varies widely across
different strains of mice [40, 45], ranging from a low of 11mmHg in the BALB/c mouse
strain to a high of 19mmHg in the CBA/Ca mouse strain. In the present study, the
average measured IOP across the 33 strains was 13.2mmHg. The lowest measured IOP
was 10.9mmHg in the DBA/2J strain and the highest was 17.1mmHg in the BXD48
strain. Using the variability across the BXD RI strains we were able to map a single
significant QTL on Chr. 8 in the mouse. The peak of the QTL was in a gene desert and
within this region there were only two potential candidate genes that could be modulating
IOP in the BXD strain set. Based on expression of mRNA in the eye microarray dataset
and the findings of real time PCR *Cdh11* appears to be the best candidate. *Cdh11* is
expressed approximately 8-fold higher in the eye than is *Cdh8*. Furthermore, previous
study [46] found *CDH11* to be highly expressed in cultured human trabecular meshwork
cells. We found that Cadherin 11 is expressed in the trabecular meshwork using indirect
immunohistochemistry. All of these data suggest that the expression Cadherin 11 in the
trabecular meshwork modulates IOP across the BXD RI strain set.

How is it possible that a cadherin can modulate IOP in the mouse eye? IOP is regulated
by fluid resistance at the trabecular meshwork and Schlemm's canal [47, 48]. The
stiffness of these structures is determined by the extracellular matrix within the trabecular
meshwork and Schlemm's canal and the contractile nature of the cells themselves (Zhou
et al. 2012) inner wall was considered to be the most important player regulating such
resistance [49-51]. The dysregulation or poor organization of extracellular matrix may
increase the fluid resistance, leading to an elevation of the IOP. *Cdh11* was recently
revealed to be a novel regulator of extracellular matrix synthesis and tissue
mechanics[52] , and it is also found to be highly expressed in cultured human trabecular
meshwork cells [46]. It is possible that the IOP can be regulated by *Cdh11* and related
pathways by altering the extracellular matrix structure of the trabecular meshwork. Future
studies about the role of *Cdh11* in the trabecular meshwork may give insights into the
mechanism of IOP modulation.

Acknowledgements: We would like to thank the Robert W Williams and his group for

providing a wealth of bioinformatic resources on GeneNetwork.org. We thank Chelsey

Faircloth for her assistance in immunostaining. This study was supported by an

Unrestricted Grand from Research to Prevent Blindness, NEI grant R01EY178841

(E.E.G.), Owens Family Glaucoma Research Fund, P30EY06360 (Emory Vision Core)

and DoD CDMRP Grant W81XWH1210-1-255 from the USA Army Medical Research

& Materiel Command and the Telemedicine and Advanced Technology (E.E.G.).

308
309 **References**
310
1.      European Glaucoma Prevention Study G, Miglior S, Pfeiffer N, Torri V,
Zeyen T, Cunha-Vaz J, Adamsons I. Predictive factors for open-angle glaucoma
among patients with ocular hypertension in the European Glaucoma Prevention
Study. Ophthalmology 2007; 114(1):3-9.
2.      Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z, Group E.
Predictors of long-term progression in the early manifest glaucoma trial.
Ophthalmology 2007; 114(11):1965-72.
3.      Medeiros FA, Sample PA, Zangwill LM, Bowd C, Aihara M, Weinreb RN.
Corneal thickness as a risk factor for visual field loss in patients with
preperimetric glaucomatous optic neuropathy. Am J Ophthalmol 2003;
136(5):805-13.
4.      Herndon LW, Weizer JS, Stinnett SS. Central corneal thickness as a risk
factor for advanced glaucoma damage. Arch Ophthalmol 2004; 122(1):17-21.
5.      Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson
CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson MR, Kass MA. The Ocular
Hypertension Treatment Study: baseline factors that predict the onset of primary
open-angle glaucoma. Arch Ophthalmol 2002; 120(6):714-20; discussion 829-30.
6.      Klein BE, Klein R, Lee KE. Heritability of risk factors for primary open-
angle glaucoma: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 2004;
45(1):59-62.
7.      Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SL,
Nishimura D, Clark AF, Nystuen A, Nichols BE, Mackey DA, Ritch R, Kalenak
JW, Craven ER, Sheffield VC. Identification of a gene that causes primary open
angle glaucoma. Science 1997; 275(5300):668-70.
8.      Wiggs JL. Genetic etiologies of glaucoma. Arch Ophthalmol 2007;
125(1):30-7.
9.      Joe MK, Sohn S, Hur W, Moon Y, Choi YR, Kee C. Accumulation of
mutant myocilins in ER leads to ER stress and potential cytotoxicity in human
trabecular meshwork cells. Biochem Biophys Res Commun 2003; 312(3):592-
600.
10.     Kasetti RB, Phan TN, Millar JC, Zode GS. Expression of Mutant Myocilin
Induces Abnormal Intracellular Accumulation of Selected Extracellular Matrix
Proteins in the Trabecular Meshwork. Invest Ophthalmol Vis Sci 2016;
57(14):6058-69.
11.     Peirce JL, Lu L, Gu J, Silver LM, Williams RW. A new set of BXD
recombinant inbred lines from advanced intercross populations in mice. BMC
Genet 2004; 5:7.
12.     Mozhui K, Ciobanu DC, Schikorski T, Wang X, Lu L, Williams RW.
Dissection of a QTL hotspot on mouse distal chromosome 1 that modulates
neurobehavioral phenotypes and gene expression. PLoS Genet 2008;
4(11):e1000260.

13.　Geisert EE, Lu L, Freeman-Anderson NE, Templeton JP, Nassr M, Wang
X, Gu W, Jiao Y, Williams RW. Gene expression in the mouse eye: an online
resource for genetics using 103 strains of mice. Mol Vis 2009; 15:1730-63.
14.　Freeman NE, Templeton JP, Orr WE, Lu L, Williams RW, Geisert EE.
Genetic networks in the mouse retina: growth associated protein 43 and
phosphatase tensin homolog network. Mol Vis 2011; 17:1355-72.
15.　Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, Wiggs JL,
John SW. Mutations in genes encoding melanosomal proteins cause pigmentary
glaucoma in DBA/2J mice. Nat Genet 2002; 30(1):81-5.
16.　Chesler EJ, Lu L, Shou S, Qu Y, Gu J, Wang J, Hsu HC, Mountz JD,
Baldwin NE, Langston MA, Threadgill DW, Manly KF, Williams RW. Complex trait
analysis of gene expression uncovers polygenic and pleiotropic networks that
modulate nervous system function. Nat Genet 2005; 37(3):233-42.
17.　Rosen GD, La Porte NT, Diechtiareff B, Pung CJ, Nissanov J, Gustafson
C, Bertrand L, Gefen S, Fan Y, Tretiak OJ, Manly KF, Park MR, Williams AG,
Connolly MT, Capra JA, Williams RW. Informatics center for mouse genomics:
the dissection of complex traits of the nervous system. Neuroinformatics 2003;
1(4):327-42.
18.　Carlborg O, De Koning DJ, Manly KF, Chesler E, Williams RW, Haley CS.
Methodological aspects of the genetic dissection of gene expression.
Bioinformatics 2005; 21(10):2383-93.
19.　Churchill GA, Doerge RW. Empirical threshold values for quantitative trait
mapping. Genetics 1994; 138(3):963-71.
20.　King R, Lu L, Williams RW, Geisert EE. Transcriptome networks in the
mouse retina: An exon level BXD RI database. Mol Vis 2015; 21:1235-51.
21.　Templeton JP, Freeman NE, Nickerson JM, Jablonski MM, Rex TS,
Williams RW, Geisert EE. Innate immune network in the retina activated by optic
nerve crush. Invest Ophthalmol Vis Sci 2013; 54(4):2599-606.
22.　Sun N, Shibata B, Hess JF, FitzGerald PG. An alternative means of
retaining ocular structure and improving immunoreactivity for light microscopy
studies. Mol Vis 2015; 21:428-42.
23.　Takahashi H, Noda S, Imamura Y, Nagasawa A, Kubota R, Mashima Y,
Kudoh J, Oguchi Y, Shimizu N. Mouse myocilin (Myoc) gene expression in ocular
tissues. Biochem Biophys Res Commun 1998; 248(1):104-9.
24.　Brubaker RF. Flow of Aqueous-Humor in Humans - the Friedenwald
Lecture. Invest Ophth Vis Sci 1991; 32(13):3145-66.
25.　Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor
dynamics: a review. Open Ophthalmol J 2010; 4:52-9.
26.　Hollows FC, Graham PA. Intra-ocular pressure, glaucoma, and glaucoma
suspects in a defined population. Br J Ophthalmol 1966; 50(10):570-86.
27.　Renard E, Palombi K, Gronfier C, Pepin JL, Noel C, Chiquet C, Romanet
JP. Twenty-four hour (Nyctohemeral) rhythm of intraocular pressure and ocular
perfusion pressure in normal-tension glaucoma. Invest Ophthalmol Vis Sci 2010;
51(2):882-9.

28. Aptel F, Weinreb RN, Chiquet C, Mansouri K. 24-h monitoring devices and
nyctohemeral rhythms of intraocular pressure. Prog Retin Eye Res 2016; 55:108-
48.
29. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, Singh K.
Relationship between intraocular pressure and primary open angle glaucoma
among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol
1991; 109(8):1090-5.
30. Cohen LP, Pasquale LR. Clinical characteristics and current treatment of
glaucoma. Cold Spring Harb Perspect Med 2014; 4(6).
31. Gedde SJ, Panarelli JF, Banitt MR, Lee RK. Evidenced-based comparison
of aqueous shunts. Curr Opin Ophthalmol 2013; 24(2):87-95.
32. Ojha P, Wiggs JL, Pasquale LR. The genetics of intraocular pressure.
Semin Ophthalmol 2013; 28(5-6):301-5.
33. Ozel AB, Moroi SE, Reed DM, Nika M, Schmidt CM, Akbari S, Scott K,
Rozsa F, Pawar H, Musch DC, Lichter PR, Gaasterland D, Branham K, Gilbert J,
Garnai SJ, Chen W, Othman M, Heckenlively J, Swaroop A, Abecasis G,
Friedman DS, Zack D, Ashley-Koch A, Ulmer M, Kang JH, Consortium N, Liu Y,
Yaspan BL, Haines J, Allingham RR, Hauser MA, Pasquale L, Wiggs J, Richards
JE, Li JZ. Genome-wide association study and meta-analysis of intraocular
pressure. Hum Genet 2014; 133(1):41-57.
34. Chang TC, Congdon NG, Wojciechowski R, Munoz B, Gilbert D, Chen P,
Friedman DS, West SK. Determinants and heritability of intraocular pressure and
cup-to-disc ratio in a defined older population. Ophthalmology 2005;
112(7):1186-91.
35. Carbonaro F, Andrew T, Mackey DA, Young TL, Spector TD, Hammond
CJ. Repeated measures of intraocular pressure result in higher heritability and
greater power in genetic linkage studies. Invest Ophthalmol Vis Sci 2009;
50(11):5115-9.
36. van Koolwijk LM, Despriet DD, van Duijn CM, Pardo Cortes LM, Vingerling
JR, Aulchenko YS, Oostra BA, Klaver CC, Lemij HG. Genetic contributions to
glaucoma: heritability of intraocular pressure, retinal nerve fiber layer thickness,
and optic disc morphology. Invest Ophthalmol Vis Sci 2007; 48(8):3669-76.
37. van Koolwijk LM, Ramdas WD, Ikram MK, Jansonius NM, Pasutto F, Hysi
PG, Macgregor S, Janssen SF, Hewitt AW, Viswanathan AC, ten Brink JB,
Hosseini SM, Amin N, Despriet DD, Willemse-Assink JJ, Kramer R, Rivadeneira
F, Struchalin M, Aulchenko YS, Weisschuh N, Zenkel M, Mardin CY, Gramer E,
Welge-Lussen U, Montgomery GW, Carbonaro F, Young TL, Group DER,
Bellenguez C, McGuffin P, Foster PJ, Topouzis F, Mitchell P, Wang JJ, Wong
TY, Czudowska MA, Hofman A, Uitterlinden AG, Wolfs RC, de Jong PT, Oostra
BA, Paterson AD, Wellcome Trust Case Control C, Mackey DA, Bergen AA, Reis
A, Hammond CJ, Vingerling JR, Lemij HG, Klaver CC, van Duijn CM. Common
genetic determinants of intraocular pressure and primary open-angle glaucoma.
PLoS Genet 2012; 8(5):e1002611.
38. Liton PB, Luna C, Challa P, Epstein DL, Gonzalez P. Genome-wide
expression profile of human trabecular meshwork cultured cells,

nonglaucomatous and primary open angle glaucoma tissue. Mol Vis 2006;
12:774-90.
39.    Burdon KP, Macgregor S, Hewitt AW, Sharma S, Chidlow G, Mills RA,
Danoy P, Casson R, Viswanathan AC, Liu JZ, Landers J, Henders AK, Wood J,
Souzeau E, Crawford A, Leo P, Wang JJ, Rochtchina E, Nyholt DR, Martin NG,
Montgomery GW, Mitchell P, Brown MA, Mackey DA, Craig JE. Genome-wide
association study identifies susceptibility loci for open angle glaucoma at TMCO1
and CDKN2B-AS1. Nat Genet 2011; 43(6):574-8.
40.    Savinova OV, Sugiyama F, Martin JE, Tomarev SI, Paigen BJ, Smith RS,
John SW. Intraocular pressure in genetically distinct mice: an update and strain
survey. BMC Genet 2001; 2:12.
41.    Struebing FL, Geisert EE. What Animal Models Can Tell Us About
Glaucoma. Prog Mol Biol Transl Sci 2015; 134:365-80.
42.    Sappington RM, Carlson BJ, Crish SD, Calkins DJ. The microbead
occlusion model: a paradigm for induced ocular hypertension in rats and mice.
Invest Ophthalmol Vis Sci 2010; 51(1):207-16.
43.    Cone FE, Gelman SE, Son JL, Pease ME, Quigley HA. Differential
susceptibility to experimental glaucoma among 3 mouse strains using bead and
viscoelastic injection. Exp Eye Res 2010; 91(3):415-24.
44.    Samsel PA, Kisiswa L, Erichsen JT, Cross SD, Morgan JE. A novel
method for the induction of experimental glaucoma using magnetic
microspheres. Invest Ophthalmol Vis Sci 2011; 52(3):1671-5.
45.    Wang WH, Millar JC, Pang IH, Wax MB, Clark AF. Noninvasive
measurement of rodent intraocular pressure with a rebound tonometer. Invest
Ophthalmol Vis Sci 2005; 46(12):4617-21.
46.    Paylakhi SH, Yazdani S, April C, Fan JB, Moazzeni H, Ronaghi M, Elahi
E. Non-housekeeping genes expressed in human trabecular meshwork cell
cultures. Mol Vis 2012; 18:241-54.
47.    Ethier CR, Kamm RD, Palaszewski BA, Johnson MC, Richardson TM.
Calculations of flow resistance in the juxtacanalicular meshwork. Invest
Ophthalmol Vis Sci 1986; 27(12):1741-50.
48.    Brubaker RF. The effect of intraocular pressure on conventional outflow
resistance in the enucleated human eye. Invest Ophthalmol 1975; 14(4):286-92.
49.    Bradley JM, Vranka J, Colvis CM, Conger DM, Alexander JP, Fisk AS,
Samples JR, Acott TS. Effect of matrix metalloproteinases activity on outflow in
perfused human organ culture. Invest Ophthalmol Vis Sci 1998; 39(13):2649-58.
50.    Johnson M. 'What controls aqueous humour outflow resistance?'. Exp Eye
Res 2006; 82(4):545-57.
51.    Vranka JA, Kelley MJ, Acott TS, Keller KE. Extracellular matrix in the
trabecular meshwork: intraocular pressure regulation and dysregulation in
glaucoma. Exp Eye Res 2015; 133:112-25.
52.    Row S, Liu Y, Alimperti S, Agarwal SK, Andreadis ST. Cadherin-11 is a
novel regulator of extracellular matrix synthesis and tissue mechanics. J Cell Sci
2016; 129(15):2950-61.
485

486    **Figures**
487
488

489
490
491    **Figure 1.**  The distribution of IOP measurements across the BXD strains is illustrated in a
492    bar chart with means and Standard Deviations.  In the 33 strains of mice the IOP ranged
493    from a low of 10.9 mmHg to a high of 17.1 mmHg.

508
509
510    **Figure 2**. A genome-wide interval map of IOP. The interval map plots the linkage
511    related score (LRS) across the genome from chromosome 1 to chromosome X. The light
512    gray line is the suggestive level and the light red line is genome-wide significance (p =
513    0.05). When the IOP measures were mapped to the mouse genome there was a significant
514    association between IOP and a locus on Chromosome 8.
515

516
517

518
**Figure 3.** The interval map for Chr. 8: 90 to 120Mb is illustrated. A is the gene tract, that

identifies the locations of known genes across the genome. B is a haplotype map for the

different BXD RI strains listed to the right and ranked from the highest IOP to the lowest

IOP. The location of genomic markers is indicated by black vertical lines. C is an

expanded version of the interval map for IOP. Finally, the bottom trace (yellow)

identified the location of SNPs between the C57BL/6 mouse and the DBA2/J mouse. The

genomic location is indicated along this lower trace. Notice that the peak of the QTL in C

sits in a region of the genome that contains very few known genes (A).

532
533
534
**F**igure 4. The distribution of cadherin 11 in the limbal area of the eye is illustrated. The

section in A was stained with an antibody specific to cadherin 11 (green) and for DNA

(blue). This staining is specific to the primary antibody for it is not observed in a section

stained with the secondary antibody alone (B). The staining pattern of the trabecular

meshwork is shown at higher magnification in C (arrow). A and B are taken at the same

magnification and the scale bar in panel B represents 25 µm.

546  **Table 1.** Primers designed for Cdh11 and Cdh8 and Myoc
547

| Cdh11 | Forward 5' GAAACCAAAGTCCCAGTGGCC 3' |
|---|---|
| | Reverse 5' TGGTCCATTGGCTGTGTCGT 3' |
| Cdh8 | Forward 5' AGCCTCCGGTCTTCTCTTCAC 3' |
| | Reverse 5' CAGTGTGGCGGTCAATGGAAA 3' |
| Myoc | Forward 5' GCTGGCTACCACGGACACTT 3' |
| | Reverse 5' CGCTCAAGTTCCAGGTTCGC 3' |
| Ppia | Mm_Ppia_1_SG QuantiTect Primer Assay |